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Introduction and Aims: High-density lipoproteins (HDL) are considered as
vasoprotective and antiatherogenic. Recent experimental findings suggest that their
biological properties can be modified in certain clinical conditions such as renal
impairment by accumulation of serum amyloid A (SAA). The effect of SAA on the
association between HDL cholesterol (HDL-C) and cardiovascular outcome remains
unknown.
Methods:We examined the associations of SAA and HDL-C with all-cause and
cardiovascular mortality in the Ludwigshafen Risk and Cardiovascular Health
(LURIC) Study including 3,310 patients undergoing coronary angiography. To validate
our findings specifically in renal patients, we analyzed 1,255 participants of the
German Diabetes and Dialysis Study (4D).
Results: In the LURIC study, SAA concentrations predicted all-cause and
cardiovascular mortality and were increased particularly in patients with renal
impairment, along with other cardiovascular risk factors. In persons with low SAA,
higher concentrations of HDL-C were associated with lower all-cause and
cardiovascular mortality. Contrarily, in patients with high SAA, higher HDL-C was
associated with increased all-cause and cardiovascular mortality indicating that SAA
indeed modifies the beneficial properties of HDL. We corroborated these clinical
observations in in-vitro experiments, where SAA had deleterious effects on vascular
functions of HDL. We further derived a formula for the simple calculation of the
amount of biologically “effective” HDL-C based on measured HDL-C and SAA from
the LURIC study. Accordingly, in the 4D study, we found that measured HDL-C was
not associated with clinical outcomes, whereas calculated “effective” HDL-C
significantly predicted better outcome.
Conclusions: The acute phase protein SAA modifies the biological effects of HDL-C in
renal patients as well as in other clinical conditions where inflammation is present. The
concomitant measurement of serum SAA is a simple, useful, and clinically applicable
method to determine the vascular functionality of HDL.
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